2016;68:252 60. S4.2-2. Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical util- ity of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. 2016;67:2578 89. S4.2-3. Nanchen D, Gencer B, Muller O, et al. Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes. Circulation. 2016;134:698 709. S4.2-4. Perak AM, Ning H, de Ferranti SD, et al. Long-term risk of athero- sclerotic cardiovascular disease in US adults with the familial hyper- cholesterolemia phenotype. Circulation. 2016;134:9 19. S4.2-5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301 7. S4.2-6. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423. S4.2-7. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. S4.2-8. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387 97. CLINICAL STATEMENTS AND GUIDELINES S4.2-9. Silverman MG, Ference BA, Im K, et al. Association between lower- ing LDL-C and cardiovascular risk reduction among different thera- peutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289 97. S4.2-10. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or with- out ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431 43. S4.2-11. Huijgen R, Abbink EJ, Bruckert E, et al. Colesevelam added to com- bination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double- blind, controlled trial. Clin Ther. 2010;32:615 25. S4.2-12. 